Artificial intelligence (AI) in pharmaceutical manufacturing remains largely confined to pilot programs, even as drugmakers test the technology to boost production and monitor quality. This push comes as the industry faces rising demand for obesity and diabetes treatments, alongside strict regulatory constraints that reward efficient, consistent output.
Operational hurdles in manufacturing
Drugmakers are testing tools like digital twins, predictive maintenance, and real-time quality monitoring to reduce downtime, limit waste, and improve batch consistency. However, a recent GlobalData report highlights significant friction points. Companies struggle with outdated legacy systems, uneven data quality, and the inherent difficulty of deploying machine learning in highly regulated environments.
Success depends on execution and the ability to combine manufacturing expertise with digital infrastructure in day-to-day workflows, said Edita Hamzic, Healthcare Analyst at GlobalData. Integrating these AI for Operations tools into existing systems remains the primary hurdle for facilities trying to scale beyond initial tests. "Companies that see AI as part of their operational model, not as a standalone technology project, are most likely to benefit," Hamzic added.
Commercial and regulatory pressures
The manufacturing push arrives as drugmakers face wider commercial pressure. A previous GlobalData report noted that delays in turning approved medicines into revenue due to pricing and reimbursement (P&R) processes have become a key challenge for the pharmaceutical sector. On regulatory and macroeconomic risks, P&R constraints ranked as the third most negative factor, cited by 22% of respondents, behind Trump administration actions and trade wars.
Regulators are actively assessing AI's role in pharmaceutical manufacturing, a critical development for the broader AI for Healthcare sector. The US Food and Drug Administration is using machine learning to help set inspection priorities under a one-day inspection pilot. Meanwhile, the European Medicines Agency is focused on ensuring transparency and maintaining human oversight.
Why this matters for healthcare professionals
Healthcare professionals working in pharmaceutical manufacturing or supply chain roles must prepare for a shift from isolated technology pilots to integrated workflows. As demand for specific treatments rises and pricing pressures tighten, facilities that successfully embed digital tools into their standard operating procedures will control their margins. Understanding how these systems function alongside regulatory requirements will be a baseline requirement for operational leadership.
Your membership also unlocks:
